Screening of NASH in Oupatients Followed in Various Hospital Specialty Clinics at the University Hospital of Strasbourg (NASH-SPE)

University Hospital, Strasbourg, France

Status: Unknown

Conditions: Nonalcoholic Fatty Liver Disease

Study type: Observational

Funder types: Other

Identifiers

NCT04282447

7376

Details and patient eligibility

About

The aim of the present study is to assess, by using a simple algorithm combining FIB-4 and Fibroscan, the prevalence of NASH with advanced fibrosis in outpatients followed in various hospital specialty clinics other than hepato/gastroenterology and to examine risk factors associated with this condition. The prevalence of NASH will be investigated among 6 cohorts of outpatients followed in different hospital specialty clinics at Hôpitaux Universitaires de Strasbourg.

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age ≥ 18 years
• outpatients followed at specialty clinics in HUS and at risk of NAFLD: with at least one metabolic risk factor (overweight, diabetes mellitus, hypertension, hypertriglyceridemia) and/or elevated transaminases and/or liver steatosis on US.
• endocrinology cohort : type 2 diabetes patients
• infectious disease cohort : HIV positive patients
• rheumatology cohort : patients with psoriasis, gout or rheumatoid arthritis
• nephrology cohort : patients with chronic kidney disease such as diabetic nephropathy or hypertensive nephropathy, including those receiving hemodialysis.
• cardiology cohorts: patients with history of angina, myocardial infarction, stroke or arteritis of lower limbs.
• internal medicine cohort: patients with auto immune systemic diseases such as lupus, sclerosis or rheumatoid arthritis.
• subjects who have given their informed consent
• Subjects affiliated to a social security system

Exclusion criteria

• alcohol consumption > 30g/d in male or > 20g/d in female in the past 6 months
• history of chronic viral hepatitis
• history of liver auto immune disease, genetic hemochromatosis, Wilson disease
• biliary disease, bile duct obstruction
• drug-induced liver injury
• secondary liver cancer or other active cancer
• organ graft
• use of medications associated with secondary NAFLD (corticosteroids, tamoxifen, amiodarone, methotrexate).
• congestive heart failure
• AIDS
• pregnancy, breastfeeding
• no information could be given to the patient (subject faces emergency situation, comprehension difficulties, etc.)
• patient under guardianship
• patients under judicial protection